aTyr Pharma reports Q4 EPS (18c), consensus (23c)

Reports collaboration and license revenue related to the Kyorin Agreement was $200K for the year ended 2024, which consisted of drug product material sold to Kyorin for the Japan portion of the EFZO-FIT study. “2024 was an important year for aTyr, as we completed enrollment in our global pivotal Phase 3 EFZO-FIT(TM) study, which is the largest interventional study ever to be conducted in pulmonary sarcoidosis, a disease where incidence and prevalence are rising yet there are still limited treatment options,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “The stage is set for 2025 to be a potential milestone year as we look toward reporting topline data for EFZO-FIT in the third quarter. Leading into this pivotal readout, we are very pleased with the execution of the study to date and the continued favorable safety profile demonstrated for efzofitimod, including our most recent positive DSMB review, which recommended the study continue as designed. Efzofitimod is poised to potentially become a safe and effective alternative to the current standard of care and improve patients’ lives.”Cash, cash equivalents, restricted cash and available-for-sale investments as of December 31, were $75.1M Subsequent to the end of the fourth quarter 2024, the Company raised approximately $18.8M in gross proceeds from its at-the-market ATM offering with Jefferies.